Myocardial fibrosis in chronic kidney disease: Potential benefits of torasemide

Kidney International

Volumn 74, Issue SUPPL. 111, 2008, Pages

  López, Begõa ^a   González, Arantxa ^a   Hermida, Nerea ^a   Laviades, Concepción ^b   Díez, Javier ^a,c,d  

^a UNIVERSITY OF NAVARRA   (Spain)

^b HOSPITAL SAN JORGE   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Arterial hypertension; Fibrosis; Heart failure; Left ventricular hypertrophy; Myocardial remodeling; Torasemide

Indexed keywords

FUROSEMIDE; LOOP DIURETIC AGENT; TORASEMIDE; DIURETIC AGENT; SULFONAMIDE;

CHRONIC KIDNEY DISEASE; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; CONFERENCE PAPER; DIASTOLIC HEART FAILURE; ELECTROLYTE BALANCE; FLUID BALANCE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEMODYNAMICS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; KIDNEY FUNCTION; PRIORITY JOURNAL; PROGNOSIS; URINARY EXCRETION; CHRONIC DISEASE; FIBROSIS; HEART DISEASE; HEART MUSCLE; KIDNEY DISEASE; PATHOLOGY; REVIEW; RISK FACTOR;

CHRONIC DISEASE; DIURETICS; FIBROSIS; HEART DISEASES; HUMANS; KIDNEY DISEASES; MYOCARDIUM; RISK FACTORS; SULFONAMIDES;

EID: 61549105632     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.512     Document Type: Conference Paper

References (40)

1. Tyralla K, Amann K. Cardiovascular changes in renal failure. Blood Purif 2002; 20: 462-465.
2. Tyralla K, Amann K. Morphology of the heart and arteries in renal failure. Kidney Int 2003; 63(Suppl. 84): S80-S83.
3. Díez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens 2007; 9: 546-550.
4. Díez J, Laviades C. Hypertensive heart disease in the patient with chronic kidney disease. Nefrología 2008; 28: 135-142.
5. Pemberton CJ, Raudsepp SD, Yandle TG et al. Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc Res 2005; 68: 109-117.
6. Hishinuma S, Funamoto M, Fujio Y et al. Hypoxic stress induces cardiotrophin-1 expression in cardiac myocytes. Biochem Biophys Res Commun 1999; 264: 436-440.
7. Levin A, Singer J, Thompson CR et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996; 27: 347-354.
8. Foley RN, Parfrey PS, Harnett JD et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192.
9. Curtis BM, Parfrey PS. Congestive heart failure in chronic kidney disease: disease specific mechanisms of systolic and diastolic heart failure and management. Cardiol Clin 2005; 23: 275-284.
10. de Almeida EA, de Oliveira EI, Lopes JA et al. Diastolic function in several stages of chronic kidney disease in patients with autosomal dominant polycystic kidney disease: a tissue Doppler imaging study. Kidney Blood Press Res 2007; 30: 234-239.
11. Díez J, González A, López B et al. Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med 2005; 2: 209-216.
12. Fatema K, Hirono O, Masakane I et al. Dynamic assessment of myocardial involvement in patients with end-stage renal disease by ultrasonic tissue characterization and serum markers of collagen metabolism. Clin Cardiol 2004; 27: 228-234.
13. Shibasaki Y, Nishiue T, Masaki H et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertens Res 2005; 28: 787-795.
14. Mark PB, Johnston N, Groenning BA et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 2006; 69: 1839-1845.
15. Laviades C, Varo N, Díez J. Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension 2000; 36: 517-522.
16. Díez J, Querejeta R, López B et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105: 2512-2517.
17. Westermann D, Kasner M, Steendijk P et al. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 2008; 117: 2051-2060.
18. Wang AY-M, Wang M, Lam CW-K et al. Left ventricular filling pressure by Doppler echocardiography in patients with end-stage renal disease. Hypertension 2008; 52: 1-8.
19. Ahmed A, Rich MW, Sanders PW et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol 2007; 99: 393-398.
20. Afshinnia F, Spitalewitz S, Chou SY et al. Left ventricular geometry and renal function in hypertensive patients with diastolic heart failure. Am J Kidney Dis 2007; 49: 227-236.
21. Das M, Aronow WS, McClung JA et al. Increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium in patients with chronic renal insufficiency. Cardiol Rev 2006; 14: 14-17.
22. Vasavada N, Agarwal R. Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int 2003; 64: 1772-1779.
23. Dunn CJ, Fitton A, Borgden R. Torasemide: an update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49: 121-142.
24. Ellison DH, Wilcox CS. Diuretics. In: Brenner BM (ed). The Kidney, 8th edn. Saunders Elsevier: Philadelphia, 2008, pp 1646-1678.
25. Cosín J, Díez J. Torasemide in chronic heart failure: results of the Toric Study. Eur J Heart Fail 2002; 4: 507-513.
26. Yamato M, Sasaki T, Honda K et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J 2003; 67: 384-390.
27. Broekhuysen J, Deger F, Douchamps J et al. Torasemide, a new potent diuretic: double-blind comparison with furosemide. Eur J Clin Pharmacol 1986; 31(Suppl): 29-34.
28. Murray MD, Deer MM, Ferguson JA et al. Open-label randomized trial of torasemide compared with furosemide therapy for patients with heart failure. Am J Med 2001; 111: 513-520.
29. López B, Querejeta R, González A et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43: 2028-2035.
30. Veeraveedu PT, Watanabe K, Ma M et al. Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy. Eur J Pharmacol 2008; 581: 121-131.
31. Veeraveedu PT, Watanabe K, Ma M et al. Comparative effects of torasemide and furosemide in rats with heart failure. Biochem Pharmacol 2008; 75: 649-659.
32. López B, González A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 859-867.
33. Shalitin N, Schlesinger H, Levy MJ et al. Expression of procollagen C-proteinase enhancer in cultured rat heart fibroblasts: evidence for coregulation with type I collagen. J Cell Biochem 2003; 90: 397-407.
34. Lee S, Solow-Cordero DE, Kessler E et al. Transforming growth factor-beta regulation of bone morphogenetic protein-1/procollagen C-proteinase and related proteins in fibrogenic cells and keratinocytes. J Biol Chem 1997; 272: 19059-19066.
35. Tsutamoto T, Sakai H, Wada A et al. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2004; 44: 2252-2253.
36. Dankwardt SM, Martin RL, Chan CS et al. Amino acid derived sulphonamide hydroxamates as inhibitors of procollagen C-proteinase: solid-phase synthesis of ornithine analogues. Bioorg Med Chem Lett 2001; 11: 2085-2088.
37. Danilowski A, Filic D, Oresic M et al. Chemistry of torasemide. Molecular and crystal structure of new polymorph N. Croat Chem Acta 2001; 74: 103-120.
38. Gropper S, Albet C, Guglietta A et al. Single-dose, randomized, cross-over bioavailability pilot clinical trial of torasemide immediate release compared to a new prolonged release formulation of torasemide. Basic Clin Pharmacol Toxicol 2006; 99(Suppl 1): 48.
39. Gropper S, Rojas MJ, Guglietta A et al. Single and repeated-dose, randomized, cross-over, bioavailability clinical trial of torasemide immediate release compared to a new prolonged release formulation of torasemide. Basic Clin Pharmacol Toxicol 2006; 99(Suppl 1): 48.
40. Roca-Cusachs A, Aracil-Vilar J, Calvo-Gómez C et al. Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: a randomized noninferiority trial versus torasemide immediate release. Cardiovasc Ther 2008; 26: 91-100.